Co-Diagnostics, Inc. (OTC: CODX)

Co-Diagnostics, Inc., a Utah-based company with the stock symbol CODX, operates in the molecular diagnostics industry. This company specializes in developing, manufacturing, and selling reagents for diagnostic tests that detect and analyze nucleic acid molecules (DNA or RNA). Co-Diagnostics' innovative molecular tools simplify complex procedures in both the development and administration of tests, providing dependable and cost-effective molecular testing for various diseases and genetic conditions.

Co-Diagnostics' business activities revolve around the design, production, and sale of proprietary reagents and tests that function via the detection and/or analysis of nucleic acid molecules. Their product portfolio includes PCR diagnostic tests for the detection of numerous diseases and pathogens, such as COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. These tests have been designed, verified, and received regulatory approvals in various countries, including the European Community, India, and the United States.

The company's revenue generation primarily comes from the sales of its reagents and diagnostic tests. Co-Diagnostics' key products and services include its proprietary test design system, which enables the design of PCR diagnostic tests, and its CoPrimer technology, enhancing the specificity and sensitivity of PCR tests. This technology is particularly beneficial for various applications, such as multiplexing, single nucleotide polymorphism (SNP) detection, and enrichment for next-generation sequencing.

Co-Diagnostics holds more than 20 granted or pending US and foreign patents, as well as certain trade secrets and copyrights, protecting its technology. The company competes in the molecular diagnostics industry with several other companies. However, Co-Diagnostics' proprietary CoPrimer technology and Co-Dx PCR platform provide a strong competitive advantage, enabling rapid, reliable, and affordable testing for various diseases.

The company's products are used by a diverse customer base, including clinical laboratories, research institutions, and government agencies around the world. Co-Diagnostics' Co-Dx PCR platform has the potential to revolutionize the field of molecular diagnostics, providing a portable diagnostic device and test system for point-of-care and at-home use.

Co-Diagnostics' product line includes the Co-Dx PCR Pro instrument, proprietary diagnostic test cups, and a mobile application, designed to provide rapid, reliable, and affordable PCR testing for various diseases, including COVID-19. The company has submitted the Co-Dx PCR platform for review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and is preparing a 510K submission for the FDA.